{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:26:17Z","timestamp":1783639577820,"version":"3.55.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-GM129325"],"award-info":[{"award-number":["R01-GM129325"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012025","name":"New York University Abu Dhabi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018786","name":"Al-Zaytoonah University of Jordan","doi-asserted-by":"publisher","award":["2025\\u20132024\/06\/28"],"award-info":[{"award-number":["2025\\u20132024\/06\/28"]}],"id":[{"id":"10.13039\/501100018786","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bioorg.2025.109165","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T07:49:30Z","timestamp":1761637770000},"page":"109165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Integrated virtual and experimental screening of natural products as potential anticancer agents against breast cancer"],"prefix":"10.1016","volume":"166","author":[{"given":"Morad","family":"Mustafa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Alwahsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lama","family":"Hamadneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashaer","family":"Abu-Irmaileh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.bioorg.2025.109165_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174287","article-title":"Breast Cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review","volume":"13","author":"Lukasiewicz","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.bioorg.2025.109165_bb0010","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/s41588-023-01507-7","article-title":"Molecular classification of hormone receptor-positive HER2-negative breast cancer","volume":"55","author":"Jin","year":"2023","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109165_bb0015","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41392-025-02181-3","article-title":"Molecular classification of hormone receptor-positive \/HER2-positive breast cancer reveals potential neoadjuvant therapeutic strategies","volume":"10","author":"Liu","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109165_bb0020","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000455820","article-title":"Biological subtypes of triple-negative breast cancer","volume":"12","author":"Hubalek","year":"2017","journal-title":"Breast Care (Basel)"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109165_bb0025","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/bcr3605","article-title":"PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data","volume":"16","author":"Zardavas","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109165_bb0030","doi-asserted-by":"crossref","unstructured":"Ali, R. and M.K. Wendt, The Paradoxical Functions of EGFR during Breast cancer Progression. Signal Transduct Target Ther, 2017. vol. 2 p. 16042-.","DOI":"10.1038\/sigtrans.2016.42"},{"issue":"23","key":"10.1016\/j.bioorg.2025.109165_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26237376","article-title":"A review of HER4 (ErbB4) kinase, its impact on Cancer, and its inhibitors","volume":"26","author":"El-Gamal","year":"2021","journal-title":"Molecules"},{"issue":"7","key":"10.1016\/j.bioorg.2025.109165_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076834","article-title":"A basic review on Estrogen receptor Signaling pathways in breast Cancer","volume":"24","author":"Clusan","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"23","key":"10.1016\/j.bioorg.2025.109165_bb0045","doi-asserted-by":"crossref","first-page":"10992","DOI":"10.1158\/0008-5472.CAN-05-2612","article-title":"Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells","volume":"65","author":"Isakoff","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109165_bb0050","doi-asserted-by":"crossref","unstructured":"Cho, Y.B. and K.S. Park, The Effect and Treatment of PIK3CA Mutations in Breast Cancer: Current Understanding and Future Directions. Medicina (Kaunas), 2025. vol. 61(3).","DOI":"10.3390\/medicina61030518"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109165_bb0055","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13058-021-01462-3","article-title":"ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer","volume":"23","author":"Brett","year":"2021","journal-title":"Breast Cancer Res."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109165_bb0060","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1124\/pharmrev.121.000381","article-title":"The yin and Yang of ERBB4: tumor suppressor and oncoprotein","volume":"74","author":"Lucas","year":"2022","journal-title":"Pharmacol. Rev."},{"issue":"D1","key":"10.1016\/j.bioorg.2025.109165_bb0065","doi-asserted-by":"crossref","first-page":"D1210","DOI":"10.1093\/nar\/gkad986","article-title":"COSMIC: a curated database of somatic variants and clinical data for cancer","volume":"52","author":"Sondka","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2025.109165_bb0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-7219-7_1","article-title":"ErbB receptors and Cancer","volume":"1652","author":"Wang","year":"2017","journal-title":"Methods Mol. Biol."},{"issue":"18","key":"10.1016\/j.bioorg.2025.109165_bb0075","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1158\/1078-0432.CCR-05-1554","article-title":"The epidermal growth factor receptor pathway: a model for targeted therapy","volume":"12","author":"Scaltriti","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"3.4","key":"10.1016\/j.bioorg.2025.109165_bb0080","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2152\/jmi.68.213","article-title":"Triple-negative breast cancer and basal-like subtype\u202f: pathology and targeted therapy","volume":"68","author":"Bando","year":"2021","journal-title":"J. Med. Invest."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109165_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16010087","article-title":"Novel HER-2 targeted therapies in breast Cancer","volume":"16","author":"Fernandes","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"Suppl. 1","key":"10.1016\/j.bioorg.2025.109165_bb0090","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.3747\/co.22.2363","article-title":"Targeted therapy in her2-positive metastatic breast cancer: a review of the literature","volume":"22","author":"Zhu","year":"2015","journal-title":"Curr. Oncol."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109165_bb0095","doi-asserted-by":"crossref","first-page":"53","DOI":"10.21037\/atm-23-153","article-title":"Twenty-five years with HER2 targeted therapy","volume":"12","author":"Jorgensen","year":"2024","journal-title":"Ann Transl Med"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109165_bb0100","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13058-021-01459-y","article-title":"Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions","volume":"23","author":"Ferraro","year":"2021","journal-title":"Breast Cancer Res."},{"issue":"24","key":"10.1016\/j.bioorg.2025.109165_bb0105","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000038508","article-title":"HER2\/PI3K\/AKT pathway in HER2-positive breast cancer: a review","volume":"103","author":"Pan","year":"2024","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.bioorg.2025.109165_bb0110","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1042\/BJ20120724","article-title":"HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells","volume":"447","author":"Amin","year":"2012","journal-title":"Biochem. J."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109165_bb0115","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109165_bb0120","first-page":"20","article-title":"Review on natural products databases: where to find data in 2020","volume":"12","author":"Sorokina","year":"2020","journal-title":"J. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109165_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12010201","article-title":"Anticancer drug discovery based on natural products: from computational approaches to clinical studies","volume":"12","author":"Chunarkar-Patil","year":"2024","journal-title":"Biomedicines"},{"issue":"12","key":"10.1016\/j.bioorg.2025.109165_bb0130","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.1021\/acs.jcim.0c00675","article-title":"ZINC20-a free Ultralarge-scale chemical database for ligand discovery","volume":"60","author":"Irwin","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2025.109165_bb0135","doi-asserted-by":"crossref","unstructured":"Irwin, J.J. and B.K. Shoichet, ZINC--a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model., 2005. 45(1): p. 177\u201382.","DOI":"10.1021\/ci049714+"},{"issue":"7","key":"10.1016\/j.bioorg.2025.109165_bb0140","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1021\/ci3001277","article-title":"ZINC: a free tool to discover chemistry for biology","volume":"52","author":"Irwin","year":"2012","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2025.109165_bb0145","doi-asserted-by":"crossref","unstructured":"Sterling, T. and J.J. Irwin, ZINC 15--Ligand Discovery for Everyone. J. Chem. Inf. Model., 2015. 55(11): p. 2324\u201337.","DOI":"10.1021\/acs.jcim.5b00559"},{"key":"10.1016\/j.bioorg.2025.109165_bb0150","first-page":"33","article-title":"Open babel: an open chemical toolbox","volume":"3","author":"O\u2019Boyle","year":"2011","journal-title":"J. Chem."},{"issue":"D1","key":"10.1016\/j.bioorg.2025.109165_bb0155","doi-asserted-by":"crossref","first-page":"D1516","DOI":"10.1093\/nar\/gkae1059","article-title":"PubChem 2025 update","volume":"53","author":"Kim","year":"2025","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109165_bb0160","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/pro.3235","article-title":"UCSF ChimeraX: meeting modern challenges in visualization and analysis","volume":"27","author":"Goddard","year":"2018","journal-title":"Protein Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109165_bb0165","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pro.3943","article-title":"UCSF ChimeraX: structure visualization for researchers, educators, and developers","volume":"30","author":"Pettersen","year":"2021","journal-title":"Protein Sci."},{"issue":"11","key":"10.1016\/j.bioorg.2025.109165_bb0170","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4792","article-title":"UCSF ChimeraX: tools for structure building and analysis","volume":"32","author":"Meng","year":"2023","journal-title":"Protein Sci."},{"issue":"46","key":"10.1016\/j.bioorg.2025.109165_bb0175","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2215621119","article-title":"Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kalpha","volume":"119","author":"Liu","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109165_bb0180","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bmcl.2004.10.036","article-title":"Estrogen receptor ligands. Part 9: Dihydrobenzoxathiin SERAMs with alkyl substituted pyrrolidine side chains and linkers","volume":"15","author":"Blizzard","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.bioorg.2025.109165_bb0185","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1073\/pnas.0708281105","article-title":"6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases","volume":"105","author":"Wood","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"19","key":"10.1016\/j.bioorg.2025.109165_bb0190","doi-asserted-by":"crossref","first-page":"13052","DOI":"10.1021\/acs.jmedchem.2c00893","article-title":"Discovery of novel allosteric EGFR L858R inhibitors for the treatment of non-small-cell lung Cancer as a single agent or in combination with Osimertinib","volume":"65","author":"Obst-Sander","year":"2022","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.bioorg.2025.109165_bb0195","doi-asserted-by":"crossref","first-page":"18756","DOI":"10.1074\/jbc.M110.206193","article-title":"Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein","volume":"286","author":"Aertgeerts","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2025.109165_bb0200","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.str.2011.03.019","article-title":"A smoothed backbone-dependent rotamer library for proteins derived from adaptive kernel density estimates and regressions","volume":"19","author":"Shapovalov","year":"2011","journal-title":"Structure"},{"key":"10.1016\/j.bioorg.2025.109165_bb0205","first-page":"12","article-title":"Improving protein-ligand binding site prediction accuracy by classification of inner pocket points using local features","volume":"7","author":"Krivak","year":"2015","journal-title":"J. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109165_bb0210","first-page":"39","article-title":"P2Rank: machine learning based tool for rapid and accurate prediction of ligand binding sites from protein structure","volume":"10","author":"Krivak","year":"2018","journal-title":"J. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109165_bb0215","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2025.109165_bb0220","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","article-title":"AutoDock Vina 1.2.0: new docking methods, expanded force field, and Python bindings","volume":"61","author":"Eberhardt","year":"2021","journal-title":"J. Chem. Inf. Model."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109165_bb0225","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/protein\/8.2.127","article-title":"LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions","volume":"8","author":"Wallace","year":"1995","journal-title":"Protein Eng."},{"issue":"10","key":"10.1016\/j.bioorg.2025.109165_bb0230","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1021\/ci200227u","article-title":"LigPlot+: multiple ligand-protein interaction diagrams for drug discovery","volume":"51","author":"Laskowski","year":"2011","journal-title":"J. Chem. Inf. Model."},{"issue":"12","key":"10.1016\/j.bioorg.2025.109165_bb0235","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1021\/ci500467k","article-title":"iLOGP: a simple, robust, and efficient description of n-octanol\/water partition coefficient for drug design using the GB\/SA approach","volume":"54","author":"Daina","year":"2014","journal-title":"J. Chem. Inf. Model."},{"issue":"11","key":"10.1016\/j.bioorg.2025.109165_bb0240","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/cmdc.201600182","article-title":"A BOILED-egg to predict gastrointestinal absorption and brain penetration of small molecules","volume":"11","author":"Daina","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2025.109165_bb0245","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109165_bb0250","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","article-title":"Natural products in drug discovery: advances and opportunities","volume":"20","author":"Atanasov","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109165_bb0255","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","article-title":"Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019","volume":"83","author":"Newman","year":"2020","journal-title":"J. Nat. Prod."},{"issue":"5698","key":"10.1016\/j.bioorg.2025.109165_bb0260","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/277665a0","article-title":"Promotion of microtubule assembly in vitro by taxol","volume":"277","author":"Schiff","year":"1979","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.bioorg.2025.109165_bb0265","first-page":"1231","article-title":"Vinca alkaloids","volume":"4","author":"Moudi","year":"2013","journal-title":"Int. J. Prev. Med."},{"key":"10.1016\/j.bioorg.2025.109165_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2019.12.008","article-title":"Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: a novel therapeutic strategy","volume":"80","author":"Tewari","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"10","key":"10.1016\/j.bioorg.2025.109165_bb0275","first-page":"6438","article-title":"Curcumin inhibits oral squamous cell carcinoma proliferation and invasion via EGFR signaling pathways","volume":"7","author":"Zhen","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.bioorg.2025.109165_bb0280","doi-asserted-by":"crossref","first-page":"3268136","DOI":"10.1155\/2021\/3268136","article-title":"Genistein: an integrative overview of its mode of action, pharmacological properties, and health benefits","volume":"2021","author":"Sharifi-Rad","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.bioorg.2025.109165_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123392","article-title":"Identifying synergistic combinations of doxorubicin-loaded polyquercetin nanoparticles and natural products: implications for breast cancer therapy","volume":"645","author":"Sunoqrot","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bioorg.2025.109165_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124674","article-title":"Development of mitoxantrone-loaded quercetin nanoparticles for breast Cancer therapy with potential for synergism with bioactive natural products","volume":"665","author":"Alkhaldi","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bioorg.2025.109165_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.ica.2025.122711","article-title":"Biological activity evaluation and molecular docking studies of newly synthesized \u03b2-ketoiminato-based palladium complexes","volume":"583","author":"Taher","year":"2025","journal-title":"Inorg. Chim. Acta"},{"key":"10.1016\/j.bioorg.2025.109165_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2025.142542","article-title":"Synthesis and anticancer activity of bis(\u03b2-ketoiminato) palladium(II) complexes of 3-[(chloro-substituted phenyl)amino]-1-phenyl-2-buten-1-one","volume":"1340","author":"Taher","year":"2025","journal-title":"J. Mol. Struct."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825010454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825010454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T12:02:26Z","timestamp":1766059346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825010454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":60,"alternative-id":["S0045206825010454"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109165","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrated virtual and experimental screening of natural products as potential anticancer agents against breast cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109165","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109165"}}